Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 11701743)

1.

Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.

Salmenkivi K, Haglund C, Ristimäki A, Arola J, Heikkilä P.

J Clin Endocrinol Metab. 2001 Nov;86(11):5615-9.

PMID:
11701743
2.

9B.09: IDENTIFICATION OF MARKERS PREDICTIVE FOR MALIGNANT BEHAVIOR OF PHEOCHROMOCYTOMAS AND PARAGANGLIOMAS.

Evenepoel L, Van Nederveen FH, Oudijk L, Papathomas TG, Restuccia DF, Belt EJ, Franssen GJ, Feelders RA, Van Eeden S, Timmers H, De Herder WW, Aydin S, Vikkula M, De Krijger RR, Dinjens WN, Persu A, Korpershoek E.

J Hypertens. 2015 Jun;33 Suppl 1:e122. doi: 10.1097/01.hjh.0000467681.47178.d5.

PMID:
26102717
3.

[New aspects of tumor pathology of the adrenal glands].

Saeger W.

Pathologe. 2015 May;36(3):301-9. doi: 10.1007/s00292-015-0020-4. German.

PMID:
25941097
4.

Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.

Oudijk L, van Nederveen F, Badoual C, Tissier F, Tischler AS, Smid M, Gaal J, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger R, Favier J.

PLoS One. 2015 Mar 20;10(3):e0121361. doi: 10.1371/journal.pone.0121361. eCollection 2015.

5.

Inhibin alpha-subunit, Melan A and MNF116 in pheochromocytomas.

Păun D, Neamţu MC, Avramescu ET, Georgescu MG, Petriş R, Terzea D, Poiană C, Păun S.

Rom J Morphol Embryol. 2014;55(3):905-8.

6.

MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.

Igaz P, Igaz I, Nagy Z, Nyírő G, Szabó PM, Falus A, Patócs A, Rácz K.

Cell Mol Life Sci. 2015 Feb;72(3):417-28. doi: 10.1007/s00018-014-1752-7. Epub 2014 Oct 9. Review.

PMID:
25297921
7.

Recurrent benign adrenal pheochromocytomas associated with hemihypertrophy.

Pikilidou M, Yavropoulou M, Katsounaros M.

Endocrinol Diabetes Metab Case Rep. 2014;2014:140041. doi: 10.1530/EDM-14-0041. Epub 2014 Jul 1.

8.

Phaeochromocytoma in a 20-year-old Nigerian, resolving the dilemma of benignity or malignancy.

Ugwumba FO, Okafor OC, Okoh AD, Ajuzieogu OV.

Clin Pract. 2012 Jan 18;2(1):e15. doi: 10.4081/cp.2012.e15. eCollection 2012 Jan 1.

9.

Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.

Białas M, Okoń K, Dyduch G, Ciesielska-Milian K, Buziak M, Hubalewska-Dydejczyk A, Sobrinho-Simoes M.

Pol J Pathol. 2013 Jun;64(2):129-35.

PMID:
23900871
10.

Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.

Fernandez MC, Martin A, Venara M, Calcagno Mde L, Sansó G, Quintana S, Chemes HE, Barontini M, Pennisi PA.

Clin Endocrinol (Oxf). 2013 Nov;79(5):623-30. doi: 10.1111/cen.12205. Epub 2013 Apr 13.

PMID:
23506534
11.

[Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].

Jiang CX, Zeng Z, Wang T, Liu X, Liu R, Li Y.

Zhonghua Bing Li Xue Za Zhi. 2011 Nov;40(11):762-6. Chinese.

PMID:
22336161
12.

The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.

Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, Krishna R, Nilubol N, Pacak K, Kebebew E.

Endocr Relat Cancer. 2012 Apr 10;19(2):157-66. doi: 10.1530/ERC-11-0308. Print 2012 Apr.

13.

Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.

Guillemot J, Thouënnon E, Guérin M, Vallet-Erdtmann V, Ravni A, Montéro-Hadjadje M, Lefebvre H, Klein M, Muresan M, Seidah NG, Anouar Y, Yon L.

J Mol Endocrinol. 2012 Feb 6;48(2):115-27. doi: 10.1530/JME-11-0077. Print 2012 Apr.

14.

Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.

Saffar H, Sanii S, Heshmat R, Haghpanah V, Larijani B, Rajabiani A, Azimi S, Tavangar SM.

Am J Clin Pathol. 2011 Mar;135(3):454-60. doi: 10.1309/AJCPI8AJLUZ3CZLN.

15.

Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers.

Murthy SR, Pacak K, Loh YP.

Cell Mol Neurobiol. 2010 Nov;30(8):1377-81. doi: 10.1007/s10571-010-9592-y.

16.

Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.

Zhu Y, He HC, Yuan F, Zhang J, Rui WB, Zhao JP, Shen ZJ, Ning G.

Endocrine. 2010 Aug;38(1):93-9. doi: 10.1007/s12020-010-9356-y. Epub 2010 Jun 18.

PMID:
20960108
17.

Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.

Thouënnon E, Pierre A, Tanguy Y, Guillemot J, Manecka DL, Guérin M, Ouafik L, Muresan M, Klein M, Bertherat J, Lefebvre H, Plouin PF, Yon L, Anouar Y.

Endocr Relat Cancer. 2010 Jun 25;17(3):637-51. doi: 10.1677/ERC-10-0109. Print 2010 Sep.

18.
19.

Stathmin as a marker for malignancy in pheochromocytomas.

Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, Hellman P, Westin G.

Exp Clin Endocrinol Diabetes. 2010 Jan;118(1):27-30. doi: 10.1055/s-0029-1202789. Epub 2009 May 15.

PMID:
19449284
20.

Pheochromocytomas.

CAHILL GF.

J Am Med Assoc. 1948 Sep 18;138(3):180-6. No abstract available.

PMID:
18877484
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk